Pathologic Complete Response in the I-SPY2 Trial

<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/august-2020/association-of-pathologic-complete-response-with-3-year-outcomes-in-the-i-spy2-trial-of-neoadjuvant-therapy-for-stage-ii-or-iii-breast-cancer/\" target=\"_blank\">Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer</a></p><p><a href=\"https://ascopost.com/news/august-2020/increased-t...